Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leuke

[News]

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

More... (http://www.news-medical.net/news/20131217/Preclinical-data-shows-BGB324-as-potential-treatment-option-for-Chronic-Myeloid-Leukemia.aspx)